STENTYS Reports First Half 2015 Financial Results

STENTYS (Paris: STNT) (FR0010949404 — STNT), a medical technology company commercializing the world’s first and only Self-Apposing^® coronary stent, today announces its half-year results for the six months ended June 30, 2015, as approved by the Board meeting of September 17, 2015.

• 2015 first-half results

* Review procedures related to the consolidated accounts at the end of June 2015 have been carried out and the review report is currently under finalization.

The Company’s financial results for the first half of 2015 are characterized by the following factors:

• the 35% growth in half-year sales to €2.6 million, following the launch of the Sirolimus-eluting stent and the Xposition^® line at the end of the period;
• the gross margin improvement, which increased from 39.1% during H1 2014 to 53% during H1 2015, and results from the lower Xposition manufacturing costs than the previous line’s costs;
• the 59% reduction in net loss to -€5.4 million, compared with -€13.2 million the prior year, driven by a decrease in operating costs and the termination of the APPOSITION V clinical trial.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, comments: "The first half of the year saw the launch of our new products, which were very well received by cardiologists as illustrated by the increase in revenues, and the improvement of the financial fundamentals. We are now in a position to seize new markets and finalize the clinical demonstration of our technology.”

To read the complete presse release, please click here.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150917006208/en/